University of California San Francisco

Thierry Marie Jahan, M.D.
Thierry Marie Jahan, MD
Professor of Medicine (Retired)
UCSF Helen Diller Family Comprehensive Cancer Center

Address

Location Required, #001
United States

Phone: 415-885-3882
Fax: 415-353-7984

Biography

Thierry M. Jahan, M.D. is a renowned medical oncologist who specializes in the treatment of thoracic malignancies such as lung cancer and mesothelioma, and soft tissue sarcomas. Dr. Jahan received his M.D. from George Washington University, thereafter completing his residency and internal medicine residency at Cedars Sinai Medical Center in Los Angeles. He later was a clinical fellows in hematology and oncology at UCSF, eventually joining the UCSF faculty. Dr. Jahan co-founded the Thoracic Oncology Program with David Jablons, M.D. 

In addition to his keen clinical insight, Dr. Jahan is known by patients, their families and fellow clinicians for his sense of empathy and compassion. His steadfast commitment to eliminating the scourge of lung cancer is evidenced by the pins and ribbons adorning his white coat, a clear message of hope to patients.

In 2016, Dr. Jahan was inducted into the Council of Master Clinicians by the UCSF Department of Medicine, a select group of outstanding physicians with exceptional knowledge, superior teaching and communication skills, and the ability to provide compassionate, appropriate, effective, and high-quality patient care. 

Dr. Jahan has been the recipient of numerous awards including the Medical House Staff Outstanding Teacher Award and Friend of the Palliative Care Service Award. He is also a member of numerous professional organizations, including the American College of Physicians, American Society of Clinical Oncology (ASCO), and International Association for the Study of Lung Cancer (IASLC) and the Association of Northern California Oncologists.

Dr. Jahan has authored or co-authored numerous peer-reviewed articles, book chapters and research abstracts and lectured nationally and internationally on lung cancer and mesothelioma. Numerous major media outlets including The San Francisco Chronicle, Time Magazine and KPIX San Francisco have sought out his opinions and observations on treatments and advances in lung cancer.

Education

Institution Degree Dept or School End Date
University of California, San Francisco Fellowship Hematology/Oncology 06/1994
University of California, Los Angeles Kennamer Fellowship Internal Medicine 06/1991
University of California, Los Angeles Residency Internal Medicine 06/1990
George Washington University School of Medicine and Health Sciences MD 06/1987
Columbia University BA Psychology 05/1983

Clinical Trials

  1. PTK787/ZK 222584 in Treating Patients With Unresectable Malignant Mesothelioma (NCT00053885)
    Related Conditions: Mesothelioma, Lung Cancer, Lung Tumor| Start Date: | End Date:

In the News

Thierry Jahan, M.D. Discusses Clinical Trial Using CRS-207 Vaccine in Mesothelioma
July, 28, 2016 | UCSF Thoracic Oncology Program
Legendary Thoracic Oncologist Thierry Jahan, M.D. Inducted into Council of Master Clinicians
July, 01, 2016 | UCSF Thoracic Oncology Program
Mulitgene Assay Better Predictor of Survival than Conventional Staging
January, 26, 2012 | UCSF Thoracic Oncology Program
Thierry Jahan Honored with Exceptional Physician Award
April, 21, 2010 | UCSF Thoracic Oncology Program
Thierry Jahan Named Bonnie J. and Anthony Addario Endowed Chair in Thoracic Oncology
June, 01, 2009 | UCSF Thoracic Oncology Program

Publications

MOST RECENT PUBLICATIONS FROM A TOTAL OF 59
  1. First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicentre, randomised, open-label, phase 3 trial.
    Baas P, Scherpereel A, Nowak AK, Fujimoto N, Peters S, Tsao AS, Mansfield AS, Popat S, Jahan T, Antonia S, Oulkhouir Y, Bautista Y, Cornelissen R, Greillier L, Grossi F, Kowalski D, Rodríguez-Cid J, Aanur P, Oukessou A, Baudelet C, Zalcman G| | View in PubMed
  2. Tazemetostat in advanced epithelioid sarcoma with loss of INI1/SMARCB1: an international, open-label, phase 2 basket study.
    Gounder M, Schöffski P, Jones RL, Agulnik M, Cote GM, Villalobos VM, Attia S, Chugh R, Chen TW, Jahan T, Loggers ET, Gupta A, Italiano A, Demetri GD, Ratan R, Davis LE, Mir O, Dileo P, Van Tine BA, Pressey JG, Lingaraj T, Rajarethinam A, Sierra L, Agarwal S, Stacchiotti S| | View in PubMed
  3. Evaluation of a National Comprehensive Cancer Network Guidelines-Based Decision Support Tool in Patients With Non-Small Cell Lung Cancer: A Nonrandomized Clinical Trial.
    Wu SY, Lazar AA, Gubens MA, Blakely CM, Gottschalk AR, Jablons DM, Jahan TM, Wang VEH, Dunbar TL, Wong ML, Chan JW, Guthrie W, Belkora J, Yom SS| | View in PubMed
  4. Therapy-Induced Evolution of Human Lung Cancer Revealed by Single-Cell RNA Sequencing.
    Maynard A, McCoach CE, Rotow JK, Harris L, Haderk F, Kerr DL, Yu EA, Schenk EL, Tan W, Zee A, Tan M, Gui P, Lea T, Wu W, Urisman A, Jones K, Sit R, Kolli PK, Seeley E, Gesthalter Y, Le DD, Yamauchi KA, Naeger DM, Bandyopadhyay S, Shah K, Cech L, Thomas NJ, Gupta A, Gonzalez M, Do H, Tan L, Bacaltos B, Gomez-Sjoberg R, Gubens M, Jahan T, Kratz JR, Jablons D, Neff N, Doebele RC, Weissman J, Blakely CM, Darmanis S, Bivona TG| | View in PubMed
  5. Clinical Response of Live-Attenuated, Listeria monocytogenes Expressing Mesothelin (CRS-207) with Chemotherapy in Patients with Malignant Pleural Mesothelioma.
    Hassan R, Alley E, Kindler H, Antonia S, Jahan T, Honarmand S, Nair N, Whiting CC, Enstrom A, Lemmens E, Tsujikawa T, Kumar S, Choe G, Thomas A, McDougall K, Murphy AL, Jaffee E, Coussens LM, Brockstedt DG| | View in PubMed
  6. Incorporation of a Molecular Prognostic Classifier Improves Conventional Non-Small Cell Lung Cancer Staging.
    Kratz JR, Haro GJ, Cook NR, He J, Van Den Eeden SK, Woodard GA, Gubens MA, Jahan TM, Jones KD, Kim IJ, He B, Jablons DM, Mann MJ| | View in PubMed
  7. Distinct attentional function profiles in older adults receiving cancer chemotherapy.
    Utne I, Løyland B, Grov EK, Rasmussen HL, Torstveit AH, Cooper BA, Mastick J, Mazor M, Wong M, Paul SM, Conley YP, Jahan T, Ritchie C, Levine JD, Miaskowski C| | View in PubMed
  8. Treatment of Malignant Pleural Mesothelioma: American Society of Clinical Oncology Clinical Practice Guideline.
    Kindler HL, Ismaila N, Armato SG, Bueno R, Hesdorffer M, Jahan T, Jones CM, Miettinen M, Pass H, Rimner A, Rusch V, Sterman D, Thomas A, Hassan R| | View in PubMed
  9. Adjuvant Chemotherapy Guided by Molecular Profiling and Improved Outcomes in Early Stage, Non-Small-Cell Lung Cancer.
    Woodard GA, Wang SX, Kratz JR, Zoon-Besselink CT, Chiang CY, Gubens MA, Jahan TM, Blakely CM, Jones KD, Mann MJ, Jablons DM| | View in PubMed
  10. Inhibiting Histone Deacetylase as a Means to Reverse Resistance to Angiogenesis Inhibitors: Phase I Study of Abexinostat Plus Pazopanib in Advanced Solid Tumor Malignancies.
    Aggarwal R, Thomas S, Pawlowska N, Bartelink I, Grabowsky J, Jahan T, Cripps A, Harb A, Leng J, Reinert A, Mastroserio I, Truong TG, Ryan CJ, Munster PN| | View in PubMed
  11. NCCN Guidelines Insights: Malignant Pleural Mesothelioma, Version 3.2016.
    Ettinger DS, Wood DE, Akerley W, Bazhenova LA, Borghaei H, Camidge DR, Cheney RT, Chirieac LR, D'Amico TA, Dilling T, Dobelbower M, Govindan R, Hennon M, Horn L, Jahan TM, Komaki R, Lackner RP, Lanuti M, Lilenbaum R, Lin J, Loo BW, Martins R, Otterson GA, Patel JD, Pisters KM, Reckamp K, Riely GJ, Schild SE, Shapiro TA, Sharma N, Swanson SJ, Stevenson J, Tauer K, Yang SC, Gregory K, Hughes M| | View in PubMed
  12. NCCN Guidelines Insights: Non-Small Cell Lung Cancer, Version 4.2016.
    Ettinger DS, Wood DE, Akerley W, Bazhenova LA, Borghaei H, Camidge DR, Cheney RT, Chirieac LR, D'Amico TA, Dilling TJ, Dobelbower MC, Govindan R, Hennon M, Horn L, Jahan TM, Komaki R, Lackner RP, Lanuti M, Lilenbaum R, Lin J, Loo BW, Martins R, Otterson GA, Patel JD, Pisters KM, Reckamp K, Riely GJ, Schild SE, Shapiro TA, Sharma N, Stevenson J, Swanson SJ, Tauer K, Yang SC, Gregory K, Hughes M| | View in PubMed
  13. Intraoperative Radiotherapy in the Management of Locally Recurrent Extremity Soft Tissue Sarcoma.
    Tinkle CL, Weinberg V, Braunstein SE, Wustrack R, Horvai A, Jahan T, O'Donnell RJ, Gottschalk AR| | View in PubMed
  14. Non-Small Cell Lung Cancer, Version 6.2015.
    Ettinger DS, Wood DE, Akerley W, Bazhenova LA, Borghaei H, Camidge DR, Cheney RT, Chirieac LR, D'Amico TA, Demmy TL, Dilling TJ, Dobelbower MC, Govindan R, Grannis FW, Horn L, Jahan TM, Komaki R, Krug LM, Lackner RP, Lanuti M, Lilenbaum R, Lin J, Loo BW, Martins R, Otterson GA, Patel JD, Pisters KM, Reckamp K, Riely GJ, Rohren E, Schild SE, Shapiro TA, Swanson SJ, Tauer K, Yang SC, Gregory K, Hughes M, National comprehensive cancer network| | View in PubMed
  15. Non-small cell lung cancer, version 1.2015.
    Ettinger DS, Wood DE, Akerley W, Bazhenova LA, Borghaei H, Camidge DR, Cheney RT, Chirieac LR, D'Amico TA, Demmy TL, Dilling TJ, Govindan R, Grannis FW, Horn L, Jahan TM, Komaki R, Kris MG, Krug LM, Lackner RP, Lanuti M, Lilenbaum R, Lin J, Loo BW, Martins R, Otterson GA, Patel JD, Pisters KM, Reckamp K, Riely GJ, Rohren E, Schild S, Shapiro TA, Swanson SJ, Tauer K, Yang SC, Gregory K, Hughes M| | View in PubMed
  16. A phase II, open-label study of ramucirumab in combination with paclitaxel and carboplatin as first-line therapy in patients with stage IIIB/IV non-small-cell lung cancer.
    Camidge DR, Berge EM, Doebele RC, Ballas MS, Jahan T, Haigentz M, Hoffman D, Spicer J, West H, Lee P, Yang L, Joshi A, Gao L, Yurasov S, Mita A| | View in PubMed
  17. Phase II clinical trial of amatuximab, a chimeric antimesothelin antibody with pemetrexed and cisplatin in advanced unresectable pleural mesothelioma.
    Hassan R, Kindler HL, Jahan T, Bazhenova L, Reck M, Thomas A, Pastan I, Parno J, O'Shannessy DJ, Fatato P, Maltzman JD, Wallin BA| | View in PubMed
  18. Prognostic molecular assay might improve identification of patients at risk for recurrence in early-stage non-small-cell lung cancer.
    Woodard GA, Gubens MA, Jahan TM, Jones KD, Kukreja J, Theodore PR, Cardozo S, Jew G, Clary-Macy C, Jablons DM, Mann MJ| | View in PubMed
  19. Divergent management strategies for typical versus atypical carcinoid tumors of the thoracic cavity.
    Okoye CC, Jablons DM, Jahan TM, Kukreja J, Cardozo S, Yom SS| | View in PubMed
  20. The impact of a fourteen-gene molecular assay on physician treatment decisions in non-small-cell lung cancer.
    Dormady S, Broder MS, Putcha GV, Dumanois RH, DeCristofaro AH, Chang E, Billings PR, Jahan T| | View in PubMed
  21. Aggressive and minimally invasive surgery for pulmonary metastasis of sarcoma.
    Reza J, Sammann A, Jin C, Horvai A, Hudnall M, Jablons DM, Jahan T, Kornak J, Mann MJ| | View in PubMed
  22. A novel use of foley catheters to prevent injury to the pelvic viscera during stereotactic radiosurgery for undifferentiated pleomorphic sarcoma of the sacrum.
    Maa J, Waterford S, Jahan T, Larson DA, Chou D| | View in PubMed
  23. VATS lobectomy facilitates the delivery of adjuvant docetaxel-carboplatin chemotherapy in patients with non-small cell lung cancer.
    Zhi X, Gao W, Han B, Yang Y, Li H, Liu D, Wang C, Min G, Long H, Rigas JR, Carey M, Jahan T, Sammann A, Reza J, Wang D, Mann MJ, Jablons DM, He J, China Clinical Trials Consortium| | View in PubMed
  24. Desmoplastic fibroma of the spine causing severe mediastinal compression and brachial plexus encasement: report of 2 cases.
    Lau D, Yarlagadda J, Jahan T, Jablons D, Chou D| | View in PubMed
  25. Non-small cell lung cancer, version 2.2013.
    Ettinger DS, Akerley W, Borghaei H, Chang AC, Cheney RT, Chirieac LR, D'Amico TA, Demmy TL, Govindan R, Grannis FW, Grant SC, Horn L, Jahan TM, Komaki R, Kong FM, Kris MG, Krug LM, Lackner RP, Lennes IT, Loo BW, Martins R, Otterson GA, Patel JD, Pinder-Schenck MC, Pisters KM, Reckamp K, Riely GJ, Rohren E, Shapiro TA, Swanson SJ, Tauer K, Wood DE, Yang SC, Gregory K, Hughes M, National comprehensive cancer network| | View in PubMed
  26. Thymomas and thymic carcinomas: Clinical Practice Guidelines in Oncology.
    Ettinger DS, Riely GJ, Akerley W, Borghaei H, Chang AC, Cheney RT, Chirieac LR, D'Amico TA, Demmy TL, Govindan R, Grannis FW, Grant SC, Horn L, Jahan TM, Komaki R, Kong FM, Kris MG, Krug LM, Lackner RP, Lennes IT, Loo BW, Martins R, Otterson GA, Patel JD, Pinder-Schenck MC, Pisters KM, Reckamp K, Rohren E, Shapiro TA, Swanson SJ, Tauer K, Wood DE, Yang SC, Gregory K, Hughes M, National Comprehensive Cancer Network| | View in PubMed
  27. Small cell lung cancer.
    Kalemkerian GP, Akerley W, Bogner P, Borghaei H, Chow LQ, Downey RJ, Gandhi L, Ganti AK, Govindan R, Grecula JC, Hayman J, Heist RS, Horn L, Jahan T, Koczywas M, Loo BW, Merritt RE, Moran CA, Niell HB, O'Malley J, Patel JD, Ready N, Rudin CM, Williams CC, Gregory K, Hughes M, National Comprehensive Cancer Network| | View in PubMed
  28. Non-small cell lung cancer.
    Ettinger DS, Akerley W, Borghaei H, Chang AC, Cheney RT, Chirieac LR, D'Amico TA, Demmy TL, Ganti AK, Govindan R, Grannis FW, Horn L, Jahan TM, Jahanzeb M, Kessinger A, Komaki R, Kong FM, Kris MG, Krug LM, Lennes IT, Loo BW, Martins R, O'Malley J, Osarogiagbon RU, Otterson GA, Patel JD, Pinder-Schenck MC, Pisters KM, Reckamp K, Riely GJ, Rohren E, Swanson SJ, Wood DE, Yang SC, Hughes M, Gregory KM, NCCN (National Comprehensive Cancer Network)| | View in PubMed
  29. Determination of cutpoints for low and high number of symptoms in patients with advanced cancer.
    Gilbertson-White S, Aouizerat BE, Jahan T, Paul SM, West C, Schumacher K, Dodd MJ, Rabow M, Abu Raddaha AH, Miaskowski C| | View in PubMed
  30. A phase II study of enzastaurin in combination with erlotinib in patients with previously treated advanced non-small cell lung cancer.
    Clément-Duchêne C, Natale RB, Jahan T, Krupitskaya Y, Osarogiagbon R, Sanborn RE, Bernstein ED, Dudek AZ, Latz JE, Shi P, Wakelee HA| | View in PubMed
  31. One size does not fit all lung cancer patients.
    Yom SS, Chen CP, Jahan TM, Jablons DM| | View in PubMed
  32. Impact of age and comorbidity on non-small-cell lung cancer treatment in older veterans.
    Wang S, Wong ML, Hamilton N, Davoren JB, Jahan TM, Walter LC| | View in PubMed
  33. A practical molecular assay to predict survival in resected non-squamous, non-small-cell lung cancer: development and international validation studies.
    Kratz JR, He J, Van Den Eeden SK, Zhu ZH, Gao W, Pham PT, Mulvihill MS, Ziaei F, Zhang H, Su B, Zhi X, Quesenberry CP, Habel LA, Deng Q, Wang Z, Zhou J, Li H, Huang MC, Yeh CC, Segal MR, Ray MR, Jones KD, Raz DJ, Xu Z, Jahan TM, Berryman D, He B, Mann MJ, Jablons DM| | View in PubMed
  34. Malignant pleural mesothelioma.
    Ettinger DS, Akerley W, Borghaei H, Chang A, Cheney RT, Chirieac LR, D'Amico TA, Demmy TL, Ganti AK, Govindan R, Grannis FW, Horn L, Jahan TM, Jahanzeb M, Kessinger A, Komaki R, Kong FM, Kris MG, Krug LM, Lennes IT, Loo BW, Martins R, O'Malley J, Osarogiagbon RU, Otterson GA, Patel JD, Schenck MP, Pisters KM, Reckamp K, Riely GJ, Rohren E, Swanson SJ, Wood DE, Yang SC, National Comprehensive Cancer Network| | View in PubMed
  35. Vatalanib in malignant mesothelioma: a phase II trial by the Cancer and Leukemia Group B (CALGB 30107).
    Jahan T, Gu L, Kratzke R, Dudek A, Otterson GA, Wang X, Green M, Vokes EE, Kindler HL| | View in PubMed
  36. Implications of delayed initiation of radiotherapy: accelerated repopulation after induction chemotherapy for stage III non-small cell lung cancer.
    Chen CP, Weinberg VK, Jahan TM, Jablons DM, Yom SS| | View in PubMed
  37. Emerging antiangiogenic therapies for non-small-cell lung cancer.
    Blakely C, Jahan T| | View in PubMed
  38. Small cell lung cancer.
    Kalemkerian GP, Akerley W, Bogner P, Borghaei H, Chow L, Downey RJ, Gandhi L, Ganti AK, Govindan R, Grecula JC, Hayman J, Heist RS, Horn L, Jahan TM, Koczywas M, Moran CA, Niell HB, O'Malley J, Patel JD, Ready N, Rudin CM, Williams CC, National Comprehensive Cancer Network| | View in PubMed
  39. Lung cancer stigma, depression, and quality of life among ever and never smokers.
    Cataldo JK, Jahan TM, Pongquan VL| | View in PubMed
  40. A review of the literature on multiple symptoms, their predictors, and associated outcomes in patients with advanced cancer.
    Gilbertson-White S, Aouizerat BE, Jahan T, Miaskowski C| | View in PubMed
  41. Measuring stigma in people with lung cancer: psychometric testing of the cataldo lung cancer stigma scale.
    Cataldo JK, Slaughter R, Jahan TM, Pongquan VL, Hwang WJ| | View in PubMed
  42. Thymic malignancies.
    Ettinger DS, Akerley W, Bepler G, Blum MG, Chang A, Cheney RT, Chirieac LR, D'Amico TA, Demmy TL, Govindan R, Grannis FW, Jahan T, Johnson DH, Kessinger A, Komaki R, Kong FM, Kris MG, Krug LM, Le QT, Lennes IT, Martins R, O'Malley J, Osarogiagbon RU, Otterson GA, Patel JD, Pisters KM, Reckamp K, Riely GJ, Rohren E, Swanson SJ, Wood DE, Yang SC, National Comprehensive Cancer Network| | View in PubMed
  43. Non-small cell lung cancer.
    Ettinger DS, Akerley W, Bepler G, Blum MG, Chang A, Cheney RT, Chirieac LR, D'Amico TA, Demmy TL, Ganti AK, Govindan R, Grannis FW, Jahan T, Jahanzeb M, Johnson DH, Kessinger A, Komaki R, Kong FM, Kris MG, Krug LM, Le QT, Lennes IT, Martins R, O'Malley J, Osarogiagbon RU, Otterson GA, Patel JD, Pisters KM, Reckamp K, Riely GJ, Rohren E, Simon GR, Swanson SJ, Wood DE, Yang SC, NCCN Non-Small Cell Lung Cancer Panel Members| | View in PubMed
  44. Differences in symptom clusters identified using occurrence rates versus symptom severity ratings in patients at the end of radiation therapy.
    Kim E, Jahan T, Aouizerat BE, Dodd MJ, Cooper BA, Paul SM, West C, Lee K, Swift PS, Wara W, Miaskowski C| | View in PubMed
  45. A phase I study of a 2-day lapatinib chemosensitization pulse preceding nanoparticle albumin-bound Paclitaxel for advanced solid malignancies.
    Chien AJ, Illi JA, Ko AH, Korn WM, Fong L, Chen LM, Kashani-Sabet M, Ryan CJ, Rosenberg JE, Dubey S, Small EJ, Jahan TM, Hylton NM, Yeh BM, Huang Y, Koch KM, Moasser MM| | View in PubMed
  46. Changes in symptom clusters in patients undergoing radiation therapy.
    Kim E, Jahan T, Aouizerat BE, Dodd MJ, Cooper BA, Paul SM, West C, Lee K, Swift PS, Wara W, Miaskowski C| | View in PubMed
  47. Impact of preoperative chemotherapy on pulmonary function tests in resectable early-stage non-small cell lung cancer.
    Rivera MP, Detterbeck FC, Socinski MA, Moore DT, Edelman MJ, Jahan TM, Ansari RH, Luketich JD, Peng G, Monberg M, Obasaju CK, Gralla RJ| | View in PubMed
  48. A review of the prevalence and impact of multiple symptoms in oncology patients.
    Esther Kim JE, Dodd MJ, Aouizerat BE, Jahan T, Miaskowski C| | View in PubMed
  49. Assessing quality of life following neoadjuvant therapy for early stage non-small cell lung cancer (NSCLC): results from a prospective analysis using the Lung Cancer Symptom Scale (LCSS).
    Gralla RJ, Edelman MJ, Detterbeck FC, Jahan TM, Loesch DM, Limentani SA, Govindan R, Peng G, Monberg MJ, Obasaju CK, Socinski MA| | View in PubMed
  50. Non-small cell lung cancer.
    Ettinger DS, Akerley W, Bepler G, Chang A, Cheney RT, Chirieac LR, D'Amico TA, Demmy TL, Feigenberg SJ, Figlin RA, Govindan R, Grannis FW, Jahan T, Jahanzeb M, Kessinger A, Komaki R, Kris MG, Langer CJ, Le QT, Martins R, Otterson GA, Patel JD, Robert F, Sugarbaker DJ, Wood DE| | View in PubMed
  51. Small cell lung cancer.
    Kalemkerian GP, Akerley W, Downey RJ, Ettinger DS, Fossella F, Grecula JC, Jahan T, Johnson BE, Kessinger A, Koczywas M, Langer CJ, Martins R, Niell HB, Pan CC, Ramnath N, Ready N, Robert F, Williams CC| | View in PubMed
  52. Neoadjuvant chemotherapy with gemcitabine-containing regimens in patients with early-stage non-small cell lung cancer.
    Detterbeck FC, Socinski MA, Gralla RJ, Edelman MJ, Jahan TM, Loesch DM, Limentani SA, Govindan R, Zaman MB, Ye Z, Monberg MJ, Obasaju CK| | View in PubMed
  53. Risk of cerebral metastases and neurological death after pathological complete response to neoadjuvant therapy for locally advanced nonsmall-cell lung cancer: clinical implications for the subsequent management of the brain.
    Chen AM, Jahan TM, Jablons DM, Garcia J, Larson DA| | View in PubMed
  54. Malignant pheochromocytomas and paragangliomas: a phase II study of therapy with high-dose 131I-metaiodobenzylguanidine (131I-MIBG).
    Fitzgerald PA, Goldsby RE, Huberty JP, Price DC, Hawkins RA, Veatch JJ, Dela Cruz F, Jahan TM, Linker CA, Damon L, Matthay KK| | View in PubMed
  55. Non-small cell lung cancer clinical practice guidelines in oncology.
    Ettinger DS, Bepler G, Bueno R, Chang A, Chang JY, Chirieac LR, D'Amico TA, Demmy TL, Feigenberg SJ, Grannis FW, Jahan T, Jahanzeb M, Kessinger A, Komaki R, Kris MG, Langer CJ, Le QT, Martins R, Otterson GA, Robert F, Sugarbaker DJ, Wood DE, National Comprehensive Cancer Network (NCCN)| | View in PubMed
  56. Small cell lung cancer clinical practice guidelines in oncology.
    Johnson BE, Crawford J, Downey RJ, Ettinger DS, Fossella F, Grecula JC, Jahan T, Kalemkerian GP, Kessinger A, Koczywas M, Langer CJ, Martins R, Marymont MH, Niell HB, Ramnath N, Robert F, Williams CC, National Comprehensive Cancer Network (NCCN)| | View in PubMed
  57. Activating mutations in the tyrosine kinase domain of the epidermal growth factor receptor are associated with improved survival in gefitinib-treated chemorefractory lung adenocarcinomas.
    Taron M, Ichinose Y, Rosell R, Mok T, Massuti B, Zamora L, Mate JL, Manegold C, Ono M, Queralt C, Jahan T, Sanchez JJ, Sanchez-Ronco M, Hsue V, Jablons D, Sanchez JM, Moran T| | View in PubMed
  58. Unusual thoracic problems in patients with malignancies: case 3. Carcinoid tumor of the thymus.
    Hansen EK, Krieg RM, Azar RJ, Jablons DM, Jahan TM, Zaloudek CJ| | View in PubMed
  59. Mechanisms of and potential treatment strategies for metastatic disease in non-small cell lung cancer.
    Maslyar DJ, Jahan TM, Jablons DM| | View in PubMed